Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …

Simple Summary Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare
lymphoma containing infrequent tumor cells (LP cells) in a background of non-neoplastic …

Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which
contributes to drug resistance, necessitating development of novel therapeutic approaches …

The fate of pyruvate is a defining feature in many cell types. One major fate is mitochondrial
entry via the mitochondrial pyruvate carrier (MPC). We found that diffuse large B cell …

Background Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with
respect to outcome. Features of the tumor microenvironment (TME) are associated with …

Macrophages are abundant immune cells in the microenvironment of diffuse large B-cell
lymphoma (DLBCL). Macrophage estimation by immunohistochemistry shows varying …

Diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise
specified (PTCL-NOS) are the most common subtypes of mature B cell neoplasm and T/NK …

B-cell non-Hodgkin lymphoma (B-NHL) evolution and treatment are complicated by a high
prevalence of relapses primarily due to the ability of malignant B cells to interact with tumor …

Cells in the tumor microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) show
enormous diversity and plasticity, with functions that can range from tumor inhibitory to tumor …

About 30% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or exhibit
refractory disease (r/r DLBCL) after first-line immunochemotherapy. Bone marrow (BM) …